Nav: Home

US Food and Drug Administration awards Critical Path Institute 3 grants, 1 contract

November 01, 2016

Tucson, November 1, 2016--The US Food and Drug Administration (FDA) has awarded Critical Path Institute (C-Path) three grants to develop data standards, as well as a contract to continue its research into drug-induced kidney injury. With these awards, the FDA continues to support C‑Path's efforts to advance translational research toward accelerating drug development and regulatory review.

With funding from the FDA grants, C-Path will collaborate with the Clinical Data Interchange Standards Consortium (CDISC) to develop data standards for HIV treatment, Clostridium difficile-associated diarrhea (CDAD), and Improved Data Standards for Animal Efficacy Studies and Natural History Studies for Animal Rule, which is centered around the CDISC SEND standard. Working together as part of the Coalition for Accelerating Standards and Therapies (CFAST), C-Path, CDISC, NCI-EVS, and TransCelerate BioPharma, Inc., have developed 23 CDISC therapeutic area data standards to date. CFAST was co-founded by C-Path and CDISC in 2012 and formed to accelerate clinical research and medical product development by creating and maintaining data standards, tools, and methods for conducting research in therapeutic areas that are important to public health.

C-Path's Predictive Safety Testing Consortium (PSTC) was awarded an FDA contract to continue its work with the Foundation for the National Institutes of Health (FNIH) to obtain regulatory endorsement (qualification) of several kidney safety biomarkers for use in drug development.

"We are gratified by the FDA's ongoing confidence in the C-Path model, its acknowledgement of the results C-Path has achieved, and its recognition of C-Path's stewardship role in the regulatory science arena and in our collaboration with FNIH's Biomarkers Consortium," says C-Path's President and CEO Martha Brumfield.

C-Path's 12 consortia have accomplished a number of the goals laid out in the FDA's 2004 Critical Path Initiative report, which identified the need for public-private partnerships that could collaborate to address translational science gaps. C-Path has received 10 letters of support for biomarkers from the FDA and the European Medicines Agency (EMA), to encourage their use in research and clinical trials for treatment of conditions such as Parkinson's disease (PD), Alzheimer's disease (AD), skeletal muscle injury, and kidney injury. C-Path has achieved biomarker qualifications for polycystic kidney disease (PKD) and kidney injury, as well as endorsement for a clinical trial simulation tool in the areas of AD. In 2015, the EMA rendered a positive qualification opinion on C-Path's Hollow Fiber System for Tuberculosis (HFS-TB) tool. In addition, C-Path's Data Collaboration Center oversees the curation and administration of extensive trial databases for PKD, multiple sclerosis, TB, Duchenne Muscular Dystrophy, PD, and AD.

About C-Path

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona. For more information, visit

The Critical Path Institute (C-Path)

Related Clinical Trials Articles:

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.
Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.
Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.